Repligen (NASDAQ:RGEN – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07, Zacks reports. Repligen had a net margin of 5.29% and a return on equity of 5.30%.
Repligen Stock Up 1.8%
Repligen stock opened at $180.17 on Tuesday. The stock has a market capitalization of $10.17 billion, a PE ratio of 246.81, a price-to-earnings-growth ratio of 3.23 and a beta of 1.08. Repligen has a twelve month low of $100.99 and a twelve month high of $198.87. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average of $177.37 and a 200-day moving average of $144.96.
Analysts Set New Price Targets
Several brokerages recently commented on RGEN. Barclays raised their price objective on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. UBS Group reissued a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Zacks Research downgraded Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Finally, Evercore restated an “outperform” rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.71.
Get Our Latest Stock Report on Repligen
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.
The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.
Featured Stories
- Five stocks we like better than Repligen
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
